Marina P. Zazanis
Corporate Officer/Principal at The Controlled Release Society
Profile
Marina P.
Zazanis is the founder who founded NMR of America, Inc. in 1983 and Kytogenics Pharmaceuticals Ltd.
in 1993.
At NMR of America, Inc., she held the title of President & Chief Executive Officer from 1983 to 2010.
Currently, Ms. Zazanis is a Member of The Controlled Release Society.
In the past, she worked as a Director at Lassonde Pappas & Co., Inc. and as President at Neogenix Oncology, Inc. in 1993.
Ms. Zazanis was also a Member at Hood College.
She received her undergraduate degree from Hood College.
Marina P. Zazanis active positions
| Companies | Position | Start |
|---|---|---|
The Controlled Release Society
 The Controlled Release Society Miscellaneous Commercial ServicesCommercial Services The Controlled Release Society is a private company that focuses on providing fundamental delivery research, development, regulatory science, and clinical translation. The company is based in St. Paul, MN. The company was founded by Agis Kydonieus. | Corporate Officer/Principal | - |
Former positions of Marina P. Zazanis
| Companies | Position | End |
|---|---|---|
Neogenix Oncology, Inc.
 Neogenix Oncology, Inc. Medical SpecialtiesHealth Technology Founded in December 2003, Neogenix Oncology is a clinical stage biotechnology company focused on developing therapeutic and diagnostic products for the early detection and treatment of cancer. The company's antibody drug candidates and diagnostics are designed to detect and target the tumor without destroying healthy cells. Neogenix Oncology is uniquely positioned to create innovative therapeutics through the use of proprietary cancer vaccines, several of which have demonstrated success in human trials. By marrying this platform with today's breakthrough technologies, the company is developing antibody therapeutics that could change the way it detects and treats cancer. | President | 01/01/1993 |
NMR of America, Inc.
 NMR of America, Inc. Engineering & ConstructionIndustrial Services Part of Medical Resources, Inc., NMR of America, Inc. is a company that specializes in machinery installation and management services. The company is based in Morristown, NJ. The company was founded by Marina P. Zazanis. NMR of America was acquired by Medical Resources, Inc. on August 30, 1996 for $38.52 million. | Founder | - |
Lassonde Pappas & Co., Inc.
 Lassonde Pappas & Co., Inc. Food: Specialty/CandyConsumer Non-Durables Lassonde Pappas & Co., Inc. engages in the manufacture of beverages. It offers juices, sparkling juice beverages, sauces, lemonades, teas, fortified drinks, enhanced water, isotonic, smoothie bases and concentrates, organic drinkable soups, and oral electrolytes. The company was founded by Clement David Pappas in 1921 and is headquartered in Carneys Point, NJ. | Director/Board Member | - |
| Hood College | Corporate Officer/Principal | - |
Kytogenics Pharmaceuticals Ltd.
 Kytogenics Pharmaceuticals Ltd. Medical SpecialtiesHealth Technology Kytogenics Pharmaceuticals, Inc. develops medical devices and drug delivery systems. It develops and markets a series of clinically significant therapies and products based on its N,O- carboxymethylchitosan chitosan derived technology and its sulfated derivative s-NOCC. The firm has also in Phase III Pivotal Clinical Trial, a polymeric gel product for surgical adhesion prevention. The company was founded by Marina P. Zazanis and Ashley J. Stevens in 1993 and is headquartered in Dartmouth, Canada. | Chief Executive Officer | - |
Training of Marina P. Zazanis
| Hood College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 5 |
|---|---|
Kytogenics Pharmaceuticals Ltd.
Kytogenics Pharmaceuticals Ltd. Medical SpecialtiesHealth Technology Kytogenics Pharmaceuticals, Inc. develops medical devices and drug delivery systems. It develops and markets a series of clinically significant therapies and products based on its N,O- carboxymethylchitosan chitosan derived technology and its sulfated derivative s-NOCC. The firm has also in Phase III Pivotal Clinical Trial, a polymeric gel product for surgical adhesion prevention. The company was founded by Marina P. Zazanis and Ashley J. Stevens in 1993 and is headquartered in Dartmouth, Canada. | Health Technology |
The Controlled Release Society
The Controlled Release Society Miscellaneous Commercial ServicesCommercial Services The Controlled Release Society is a private company that focuses on providing fundamental delivery research, development, regulatory science, and clinical translation. The company is based in St. Paul, MN. The company was founded by Agis Kydonieus. | Commercial Services |
Lassonde Pappas & Co., Inc.
Lassonde Pappas & Co., Inc. Food: Specialty/CandyConsumer Non-Durables Lassonde Pappas & Co., Inc. engages in the manufacture of beverages. It offers juices, sparkling juice beverages, sauces, lemonades, teas, fortified drinks, enhanced water, isotonic, smoothie bases and concentrates, organic drinkable soups, and oral electrolytes. The company was founded by Clement David Pappas in 1921 and is headquartered in Carneys Point, NJ. | Consumer Non-Durables |
NMR of America, Inc.
NMR of America, Inc. Engineering & ConstructionIndustrial Services Part of Medical Resources, Inc., NMR of America, Inc. is a company that specializes in machinery installation and management services. The company is based in Morristown, NJ. The company was founded by Marina P. Zazanis. NMR of America was acquired by Medical Resources, Inc. on August 30, 1996 for $38.52 million. | Industrial Services |
Neogenix Oncology, Inc.
Neogenix Oncology, Inc. Medical SpecialtiesHealth Technology Founded in December 2003, Neogenix Oncology is a clinical stage biotechnology company focused on developing therapeutic and diagnostic products for the early detection and treatment of cancer. The company's antibody drug candidates and diagnostics are designed to detect and target the tumor without destroying healthy cells. Neogenix Oncology is uniquely positioned to create innovative therapeutics through the use of proprietary cancer vaccines, several of which have demonstrated success in human trials. By marrying this platform with today's breakthrough technologies, the company is developing antibody therapeutics that could change the way it detects and treats cancer. | Health Technology |
- Stock Market
- Insiders
- Marina P. Zazanis
